Increasing evidence suggests that PDZK1 plays a role in inhibiting tumor progression and enhancing sensitivity to chemotherapeutic agents, highlighting its potential as a promising therapeutic target (Ma et al. 2024; Qi et al. 2020; Wang et al. 2024). The gene discussed is PDZK1; the disease is neoplasm.